Johnson & Johnson

New Brunswick, New Jersey
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Johnson & Johnson scored a 100 out of 100 on the 2023-2024 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Johnson & Johnson (J&J), increases the risk of dividing employees, alienating customers and harming shareholders. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. J&J forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company provides a benefits package for employees which covers travel/lodging costs for an abortion and transgender medical procedures for covered employees and dependents, including children. The company is a member of the Global Alliance for Responsible Media, which aims to demonetize advertisements and suppress content that “vilifies” individuals based on sexual orientation and gender identity, discusses "debated social issues in a negative or partisan context" or spreads "hate speech". J&J rolled out global unconscious bias training for all its employees. The company is a founding member of the PGLE which is an LGBTIQ+ equality and inclusion advocacy group. This reflects J&J's commitment to “operationalize” company coverage of transgender surgery and treatment, the vetting of business partners based on LGBTQ+ policies, and the financial support of LGBTQ organizations on a global level. The company signed an open letter in support of the Equality Act, a controversial bill. J&J opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. The company spoke out against the Georgia voting integrity legislation. J&J opposed legislation in Iowa intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. The company opposed the Florida Parental Rights in Education Act, which would prohibit teaching gender identity and sexual orientation to kids in K-3rd grade. J&J’s CEO Joaquin Duato is a member of the Business Roundtable and Former CEO Alex Gorsky signed its 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism over traditional obligations to shareholders and customers. The company’s CEO, signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. J&J is a bronze sponsor of the HRC and a corporate partner of the NGLCC. The company has a matching gift program to Planned Parenthood and has pledged $10 million over a span of three years to the BLM movement and related causes. J&J is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. The company donated to the Equality PAC and lobbied for ideological purposes. For these reasons, J&J receives a High Risk rating.

View Full Corporate Bias Ratings Report

Board Bias

Expand Summary

CEO of Johnson & Johnson

Joaquin B. Duato

Joaquin B. Duato


Headquartered in New Brunswick, New Jersey, Johnson & Johnson is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Joaquin B. Duato and Joaquin B. Duato serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $128,600 to Republican causes and $158,900 to Democratic causes. Under their tenure, Johnson & Johnson currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:





Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
4/25/24SocialNational Legal and Policy CenterShareholder Proposal- Gender-Based Compensation Gaps and Associated RisksAgainst3.86%
4/25/24SocialMercy Investment ServicesImpact of Extended Patent Exclusivities on Patient AccessAgainst89.96%
5/31/23SocialJubitz FoundationShareholder proposal to discontinue the development of a non-lethal TASER drone systemAgainst0.00%
4/27/23GovernanceHal Scott/Doris Behr 2012 Irrevocable TrustAdopt Federal Securities Laws Mandatory Arbitration Bylawagainst0.00%
4/27/23SocialOxfam America, Inc.Vaccine Pricing ReportAgainst31.30%
4/27/23SocialMercy Investment Services, Inc.Impact of Extended Patent Exclusivities on Product AccessAgainst14.20%
4/28/22SocialMercy Investment ServicesThird Party Racial Equity AuditAgainst62.64%
4/28/22GovernanceVermont Pension Investment CommitteeAdopt Policy to Include Legal & Compliance Costs in Incent. Compensation MetricsAgainst47.71%
4/28/22SocialSHARE (Sharehldr Assoc for Research & EducThird Party Report on Lobbying Activities Alignment with Public StatementsAgainst43.26%
4/28/22SocialOxfam America, Inc.Report on Government Financial Support & Access to COVID-19 VaccinesAgainst33.80%
4/28/22SocialTulipshare Ltd.Discontinue Global Sales of Baby Powder Containing TalcAgainst15.63%
4/28/22GovernanceMyra K. YoungConsider Pay Disparity Between Executives and Other EmployeesAgainst10.83%
4/28/22SocialHarrington Investments, Inc.Report on Public Health Costs of Protecting Vaccine TechnologyAgainst8.68%
4/28/22SocialNational Legal and Policy CenterRequest for Charitable Donations DisclosureAgainst4.07%
4/28/22SocialNational Center for Public Policy ResearchCivil Rights, Equity, Diversity & Inclusion AuditAgainst2.74%
Generate Reports